Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >=  days after the last dose of agent
For patients with solid tumors, the following criteria apply: a. Hemoglobin ? . g/dl, b. Absolute lymphocyte count ? . x ^/L, c. Absolute neutrophil count ? . x ^/L, d. Platelets ? . x ^/L
Inadequate hematologic function (unless due to underlying lymphoma), defined as follows: Hemoglobin less than (<)  grams per decilitre (g/dL), absolute neutrophil count (ANC) <.*^ cells per liter (cells/L), platelet count <*^ cells/L
Serum hemoglobin ?  g/dL; absolute neutrophil count ? . x /L; platelets ?  x /L.
Has adequate bone marrow function, defined as: Platelet count >=  x /L Hemoglobin >= . g/dL Absolute neutrophil count >= . x /L.
At least one cytopenia (ANC < /L or platelet count < ,/L or hemoglobin [Hgb] <  g/dL)
Bone marrow reserve consistent with: absolute neutrophil count ? . x /L, platelet count ?  x /L, and hemoglobin ?  g/dL (without transfusion) within  week preceding the administration of the study drugs;
Absolute neutrophil count ? . x ?/Liters (L) (/cubic millimeters)
Platelet count ?   /L, hemoglobin ? . g/dL and absolute neutrophil count (ANC) ? .   /L.
Platelet count ? ,, hemoglobin ?  g/dL
Platelet count >  /mm, hemoglobin (Hb) >  g/dL, absolute neutrophil count (ANC) /mm; the patient cannot be transfused in order to meet study entry criteria
International normalized ratio (INR) =< \r\n* If a patients bone marrow function falls below the indicated values and it is not thought to be related to prior treatments a hematology consult will be ordered; if hematology deems the patients safe to proceed with treatment they will be allowed to enroll on study; in such cases, the patients absolute neutrophil count must be > ,/mcl, hemoglobin must be > . g/dL and the platelet count must be > , mcL; each patient will also be seen by a medical oncologist at follow-up visits if possible
Adequate hematologic function as indicated by i. Absolute neutrophil counts (ANC) ? ,/mm ii. Hemoglobin (Hgb) ? . g/dL iii. Platelet count ? ,/mm
Within  days of treatment initiation: Hematological\r\n* It is anticipated that refractory AML patients will have low hematological counts including platelet count, hemoglobin, and absolute neutrophil count. Thus, hematologic parameters will not be used for enrollment and initiation of treatment
Hemoglobin ?. g/dL. Absolute neutrophil count ?. x /L and platelet count ? x /L
have adequate hematologic function, defined as having a hemoglobin ?g/dL, an absolute neutrophil count (ANC) ?.  /L, and platelet count ?. x /L;
Bone marrow reserve consistent with absolute neutrophil count (ANC) >=  per micro liter (/mcL); platelet count >= ,/mcL; hemoglobin Ac (HbAc) less than (<) . percent (%).
Absolute neutrophil count (ANC) >= . x ^/L\r\n* By automated or manual review, whichever is greatest
Absolute neutrophil count (ANC) ?. x /l, hemoglobin ? g/dl, platelet count ?  x ^/l, prothrombin (INR) <..
Subjects with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal disease (estimated glomerular filtration rate (eGFR) <ml/min), hepatic (Alanine transaminase (ALT) . times upper limit of normal (>.xULN), bilirubin > x ULN), hematological (absolute neutrophil count (ANC) <. x /L, platelet count <x/L or requires regular platelet transfusions to maintain a platelet count ?  x /L , hemoglobin <g/dL), endocrine (glycated Haemoglobin (HbAc)>% or random glucose >mg/dL), pulmonary (Forced Expiratory Volume in  second (FEV) <% of predicted value), cardiac (New York Heart Association (NYHA)) class III/IV, or neurological disease
Recovery from last induction course of chemotherapy (absolute neutrophil count [ANC] >  and platelet > ,)
No significant anemia (hemoglobin below . g/dL) or neutropenia (absolute neutrophil count [ANC] < /mm^)
Absolute neutrophil count (ANC) of < ./L, or platelet count of <  /L, or hemoglobin < g/dL;
Adequate bone marrow function: WBC > /?L; platelet count > ,/?L; Neutrophil count > /?L, without use of colony stimulating factors (CSF).
Bone marrow impairment as evidenced by hemoglobin <. g/dL, neutrophil count <.  /L, platelets <  /L
Adequate bone marrow function as defined below: \r\n Absolute neutrophil count ? .x /L ( per mm) \r\n Platelets ? x /L (, per mm) \r\n Hemoglobin > . g/dL
Peripheral blood (PB) showing at least two of the following criteria: Absolute neutrophil count (ANC) < . k/L Platelet count <  k/L Absolute reticulocyte count < ,/L
Has hemoglobin ?  g/dL, ANC ? .  /L, and platelet count ?   /L
Absolute neutrophil count < ,/?L, platelet count < ,/?L, or hemoglobin < . mmol/L ( g/dL) at screening
Patients must have a platelet count > ,/L, hemoglobin ? . gm/dL, white blood cell count (WBC) > ,/uL, absolute neutrophil count (ANC) ? . x /L, and a serum creatinine ? . mg/dL unless the measured creatinine clearance is >  mL/min/. m.
In patients <  years of age, moderately severe aplastic anemia is defined as having at least one of the following:\r\n* Platelet count <  x ^/L\r\n* Absolute neutrophil count (ANC) <  x ^/L\r\n* Hemoglobin (Hgb) <  g/dL
In patients - years of age, moderately severe aplastic anemia is defined as having at least one of the following:\r\n* Platelet count <  x ^/L\r\n* ANC <  x ^/L\r\n* Hgb <  g/dL
Laboratory test results within these ranges: Absolute neutrophil count ? . x /L, Platelet count ?  x /L, Serum creatinine ? . mg/dL, Total bilirubin ? . mg/dL, AST & ALT ?  x ULN
Anticancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count [ANC] counts): ? days after the last dose of agent.
Absolute granulocyte count of ?,/?L, platelet count ?,/?L, and hemoglobin ?. g/dL, with no transfusion within the preceding  days
Adequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ? /?l, Platelets ? ,/?l,Hemoglobin ? . g/dl, Creatinine < . mg/dl
Bone Marrow Reserve: absolute neutrophil count ? . x ^/L; platelet count ?  x ^/L; hemoglobin ? . g/dL. Must not have required blood transfusion within  week of baseline blood count assessment.
Adequate hematologic function: Absolute neutrophil count (ANC) ? . /L, platelet count ? . /L and hemoglobin ? . g/dL (patients with bone marrow involvement will not be evaluable for hematologic DLT and can enroll with ANC ? . /L, platelet count ? . /L and hemoglobin ? . g/dL)
Absolute neutrophil count (ANC) ?. x  /L, hemoglobin ? g/dL, and platelet count ?  x /L.
Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ? . x /L, platelet count ? x /L, hemoglobin >. g/dL. For Portion B: ANC ? . x /L, platelet count ?  x /L, and hemoglobin ? . g/dL. In both cases, patients must be transfusion independent at least  days prior to screening.
Inadequate bone marrow function per protocol-specified hemoglobin, platelet count, and absolute neutrophil count
Platelet count <  x^/L or absolute neutrophil count (ANC) <  x^/L at the Screening visit
Patient must have adequate bone marrow function as evidenced by absolute neutrophil count ?. ^/L; hemoglobin > g/dL (Patients are allowed to be transfused to this level); platelets ?  ^/L
Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within  weeks prior to first dose of study drug.
Subject has absolute neutrophil count < /?L, platelet count < /?L or hemoglobin <  g/dL (. mmol/L).
Blood counts at screening: haemoglobin ? . g/dl,absolute neutrophil count ? /l, platelet count ? ,/l.
Absolute neutrophil count < /?L, platelet count < ,/?L, or hemoglobin <  g/dL (. mmol/L) at screening;
Hematological: Absolute neutrophil count ?x^/L; Platelet count ?x^/L;Hemoglobin ?g/dL
Adequate bone marrow function as assessed by absolute neutrophil count (ANC) ? /mm; hemoglobin ? . g/dL, and platelet count ? ,/mm.
Bone marrow reserve: Absolute neutrophil count (ANC) ? . x /L. Platelets ?  x /L. Hemoglobin ?  g/dL.
Hematological function: hemoglobin > g/dL; lymphocyte count >. x /L; neutrophil count >. x /L; platelet count > x /L
Patients with severe hematopoietic insufficiency, as defined by an absolute neutrophil count of less than /MuL, unless disease-related, and/or a platelet count of less than ,/MuL at time of screening for this protocol
There is no specific platelet and absolute neutrophil count that will exclude patients from this study given the natural history of AML
Adequate hematology laboratory results (absolute neutrophil count ? . x ^/L, platelet count ?  x ^/L, hemoglobin ? . g/dL).
Has adequate bone marrow function defined as a hemoglobin >  g/dL, absolute neutrophil count (ANC) ?. ?/L , and platelet count ?,/mm. For subjects who received chemotherapy for melanoma just prior to screening for the study subject needs to have a hemoglobin >  g/dL, absolute neutrophil count (ANC) >  ?/L, and platelet count ?,/mm.
Previously untreated subjects that meet ANY of the following criteria:\r\n* Subjects that refuse to be treated with chemotherapy based agents (this should be documented in the consent form)\r\n* Subjects that are not candidates for treatment with chemotherapy agents based on ANY of the following:\r\n** ECOG performance status >= \r\n** Advance age (>=  years)\r\n** Cumulative Illness Rating Scale (CIRS score) >= \r\n** Cytopenias\r\n*** Hemoglobin (Hb) =<  g/L ( g/dL)\r\n*** Platelet count =<  x ^/L (,/uL)\r\n*** Absolute neutrophil count (ANC) =< . x ^/L (,/uL)
Screen labs of Hemoglobin, platelets, absolute neutrophil count (ANC), bilirubin, AST, ALT, serum creatinine, serum albumin, PT/INR, and PTT within specified values/criteria per protocol prior to dosing.
Adequate hematologic, hepatic, and renal function (absolute neutrophil count ?.x /L, Hgb > g/dL, platelet count ? x /L, AST/ALT ?.x ULN, creatinine ?.x ULN).
Prior to day  of brentuximab vedotin, patients must again meet the following criteria:\r\n* Hemoglobin >=  g/dL\r\n* Absolute neutrophil count (ANC) >= , cells/mm^\r\n* Platelet count >= ,/mm^\r\n* Maximum Child-Pugh score of \r\n* Creatinine clearance >  mL/min via Cockcroft and Gault
Patients who have had count recovery (absolute neutrophil count [ANC] > ,/mm^; non transfused platelet count over ,/mm^) and are at least  days after induction and/or transplantation but no more than  days post transplant
Platelet count >   ^/L and WBC count < .  ^/L or hemoglobin <  g/dL at any dose of hydroxyurea.
Adequate hematological function defined by white blood cell (WBC) count ?  ^/L; absolute neutrophil count (ANC) ?.  ^/L; lymphocyte count ?.  ^/L; platelet count ?  ^/L; and hemoglobin ? g/dL (may have been transfused).
Adequate hematological function, defined as WBC ?  ^/L; ANC ?.  ^/L; lymphocyte count ?.  ^/L; platelet count ?  ^/L; and hemoglobin ? g/dL (may have been transfused).
Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ? /l, platelet count ? ,/l (transfusion independent) and hemoglobin ? . gm/dL
No unexplained absolute eosinophil count > .x^/L
Group : Patients who meet group  inclusion criteria but may have FVC or DLCO-adjusted less than % plus have had an adverse event on cyclophosphamide preventing its further use (specifically hemorrhagic cystitis, leukopenia with white blood cell [WBC]<  or absolute neutrophil count [ANC] <  or platelet count < ,)
Adequate bone marrow function (hemoglobin ? . g/dL; platelets ?  x^ cells/L; absolute neutrophil count ? .x^ cells/L).
Adequate bone marrow function (hemoglobin ? . g/dL; unsupported platelets ?  cells/L; absolute neutrophil count [ANC] ? . cells/L without the use of hematopoietic growth factors)
Absolute neutrophil count < ,/?L, platelet count < ,/?L, or hemoglobin < . mmol/L ( g/dL) at screening.
Subjects must have adequate bone marrow function as assessed by the following: hemoglobin >=. g/dL or >=. mmol/L, absolute neutrophil count (ANC) >=./mm^ or >=. x ^/L (CTCAE Grade <=), platelet count >= /mm^ or >= x ^/L
Adequate bone marrow function (hemoglobin ?. g/dL; platelets ? x^ cells/L; absolute neutrophil count ?.x^ cells/L) without the use of hematopoietic growth factors.
Hematologic function: Absolute neutrophil count (ANC) > /?L and platelet count > ,/?L without transfusion
Hematological: Absolute neutrophil count (ANC) ? . x ^/L, platelet ?  x ^/L, hemoglobin ?  g/dL
. Adequate bone marrow function (hemoglobin ? . g/dL; platelets ?  x /L; absolute neutrophil count [ANC] ? . x /L) without the use of hematopoietic growth factors.
The following laboratory parameters must be within the ranges specified: Hemoglobin ?  g/dL, Neutrophil count ? . x /L, Lymphocyte count ? LLN Platelet count ?  x /L, Serum creatinine ?  mg/dL, Serum bilirubin ?  x ULN, AST/ALT ?  x ULN.
Platelet count ?  x /L, absolute neutrophil count (ANC) ? . x /L, Hemoglobin ?  g/dL.
Hemoglobin ? . g/dL, - Absolute neutrophil count ? . x /L (/mm), - Platelets ? ,/?L
Subject has absolute neutrophil count < /?L, platelet count < ,/?L, and hemoglobin <  g/dL (<  mmol/L) at Screening
Adequate bone marrow function (subjects other than those with AITL) as evidenced by: absolute neutrophil count ?. /L;hemoglobin > g/dL (Subjects may be transfused red blood cells to this level.); platelets ?  /L
Has adequate bone marrow function, defined as: Platelet count >=  X */L Hemoglobin level >= . g/dL Absolute neutrophil count >= . x */L
Adequate baseline hematological parameters as defined by white blood cell count (WBC) ? . x /L, lymphocyte count ? . x /L, platelet count ?  x /L, and hemoglobin ?  g/dL
Platelet count ? ,/cubic millimeters (mm), hemoglobin (Hb) ? . g/dl, leukocyte count > ,/mm, absolute neutrophil count (ANC) ? ,/mm
Patients must have adequate bone marrow function, defined as an absolute neutrophil count >= . x ^/L and a platelet count >=  x ^/L.
Whole Blood Cells (WBC) ?. x ?/L, Absolute neutrophil count (ANC) ?. x ?/L and platelet count ? x ?/L
Hemoglobin ? . mg/dl . Absolute neutrophil count ? . x ^/L . Platelets ?  x ^/L . Life expectancy ?  months
Bone marrow: Absolute Neutrophil Count (ANC) ? . x /L, Hemoglobin (Hgb) ?  g/dL, Platelets ?  x /L
The participant has adequate hematologic function as defined by absolute neutrophil count ? /microliters (?L), hemoglobin ?  gram/deciliter (g/dL), and platelet count ?,/?L
Neutropenia (absolute neutrophil count < .) (bloodwork is not required if patient did not have recent chemotherapy within last  weeks)
Anticipated or documented prolonged neutropenia (absolute neutrophil count [ANC] < /mm^ [. x ^/L]) at baseline or likely to develop within  to  days and lasting for at least  days due to:
Bone marrow function: neutrophil count >/=,/mm, platelet count >/= ,/mm and hemoglobin concentration >/= . g/dL.
Acceptable laboratory results during screening and prior to first study drug administration of the following parameters: absolute neutrophil count (ANC), platelet count, hemoglobin, total bilirubin, aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT), renal function based on estimated creatinine clearance
Adequate bone marrow function, defined as an absolute neutrophil count (ANC) of greater than or equal to (>=) .* per liter (/L), platelet count >=*/L, and hemoglobin >= gram per deciliter (g/dL). Receiving transfusions or hematopoietic growth factors to meet enrollment criteria is not allowed within  days preceding the first dose of study drug.
Platelet count ?  x /l, hemoglobin ? . g/dl and ANC ? . x /l.
Absolute neutrophils count (ANC) ? . x E/L, platelets ?  x E/L, hemoglobin >  g/dL (without transfusion or erythropoiesis stimulating agents dependency).
Hemoglobin must be >= gram per deciliter (g/dL), absolute neutrophil count (ANC) must be >= per microliter (/mcL), and platelet count must be >=,/mcL.
Bone marrow reserve consistent with absolute neutrophil count (ANC) ?.*^/L; platelet count ?*^/L; hemoglobin (Hgb) ? g/dL.